Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.

Autor: Guo-Qing Tang, Yalan Tang, Dhamnaskar, Ketki, Hoarty, Michelle D., Vyasamneni, Rohit, Vadysirisack, Douangsone D., Zhong Ma, Nanqun Zhu, Jian-Guo Wang, Bu, Charlie, Cong, Bestine, Palmer, Elizabeth, Duda, Petra W., Sayegh, Camil, Ricardo, Alonso

Publikováno v: Frontiers in Immunology; 2023, p1-11, 11p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.

Autor: Tang GQ; UCB Pharma, Cambridge, MA, United States., Tang Y; UCB Pharma, Cambridge, MA, United States., Dhamnaskar K; Ra Pharmaceuticals, Cambridge, MA, United States., Hoarty MD; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Vyasamneni R; Ra Pharmaceuticals, Cambridge, MA, United States., Vadysirisack DD; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Ma Z; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Zhu N; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Wang JG; UCB Pharma, Cambridge, MA, United States., Bu C; UCB Pharma, Cambridge, MA, United States., Cong B; UCB Pharma, Cambridge, MA, United States., Palmer E; UCB Pharma, Cambridge, MA, United States., Duda PW; UCB Pharma, Cambridge, MA, United States., Sayegh C; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Ricardo A; Ra Pharmaceuticals, Cambridge, MA, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Sep 25; Vol. 14, pp. 1282155. Date of Electronic Publication: 2023 Sep 25 (Print Publication: 2023).